Business World: Biogen Idec, Elan, & Tysabri (Natalizumab)

From today's Boston Globe:

A fourth death may be tied to Biogen's MS drug
Finding could be blow to marketplace hopes
By Jeffrey Krasner,
Boston Globe Staff
June 2, 2005

Biogen Idec Inc. has told the Food and Drug Administration that a fourth patient may have contracted a potentially deadly brain disease after being treated with the company's multiple sclerosis drug Tysabri.

[ ... Read the full article ... ]
-
Anthony H. Risser | neuroscience | neuropsychology | brain